^
    Back
    Association details:
    Biomarker:BRAF V600
    Cancer:Rectal Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor) +
    Braftovi (encorafenib) (BRAF inhibitor, cRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Rectal cancer:.Primary treatment…Encorafenib + (cetuximab or panitumumab) (BRAF V600E mutation positive